双免疫检查点抑制剂联合安罗替尼治疗腺泡状软组织肉瘤1例报告  

Dual immune checkpoint inhibitors combined with anlotinib in the treatment of alveolar soft part sarcoma:a case report

作　　者：方杏华 李伟[2] 周宇红[2] FANG Xinghua;LI Wei;ZHOU Yuhong(Department of Oncology,Shanghai Wusong Central Hospital,Shanghai 200940,China;Department of Oncology,Zhongshan Hospital,Fudan University,Shanghai 200032,China)

机构地区：[1]上海市吴淞中心医院肿瘤科,上海200940 [2]复旦大学附属中山医院肿瘤科,上海200032

出　　处：《中国临床医学》2025年第1期140-144,共5页Chinese Journal of Clinical Medicine

摘　　要：回顾性分析1例就诊于复旦大学附属中山医院的腺泡状软组织肉瘤(alveolar soft part sarcoma,ASPS)患者的诊治资料。患者初诊为腹腔ASPS伴两肺多发转移,接受纳武利尤单抗+伊匹木单抗治疗6周后评估为疾病稳定(stable disease,SD);第7周开始接受双免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)联合安罗替尼治疗:纳武利尤单抗(300 mg,d1,每3周1次)+安罗替尼(8 mg,d1~14,每3周1次)+伊匹木单抗(50 mg,d1,每6周1次)。患者第12周疗效评估仍为SD,给予髂动脉栓塞术及腰大肌病灶容积旋转调强放疗,并维持双ICIs联合安罗替尼治疗,第24周评估为原发病灶及肺部转移灶部分缓解(partial remission,PR)。治疗期间患者耐受性较好,不良反应轻微。Clinical data of a patient with alveolar soft part sarcoma(ASPS)treated at Zhongshan Hospital,Fudan University were retrospectively analyzed.The patient was initially diagnosed with abdominal ASPS with multiple lung metastases.After 6 weeks of treatment with nivolumab and ipilimumab,the patient achieved stable disease(SD).In the 7th week,the treatment was changed to a combination of nivolumab(30 mg,d1,q3w),anlotinib(8 mg,d1-14,q3w)and ipilimumab(50 mg,d1,q6w).The patient remained SD at the 12th week.The patient then underwent iliac artery embolization and intensity-modulated radiation therapy for the lesion in the psoas major muscle,while continuing the combination treatment.By the 24th week,the evaluation showed partial remission(PR)of both primary tumor and lung metastases.The patient experienced mild adverse reactions during treatment.

关 键 词：腺泡状软组织肉瘤 免疫检查点抑制剂 血管抑制剂 

分 类 号：R738.6[医药卫生—肿瘤]